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In many, but not all, genetic (metabolic) conditions, biochemical markers exist that are often 
basis for diagnosis and sometimes also for monitoring of patients. However, these markers are 
not always relevant for the pathogenesis of the respective conditions. For instance, in the 
classical urea cycle disorder citrullinemia type 1 1, the name-giving metabolite citrulline, an 
amino acid, is largely elevated in blood and urine of affected patients but has no known role in 
the pathogenesis of the condition (but rather the accompanying hyperammonemia). In other 
conditions, the abnormal metabolite is crucial for developing disease. An illustrious example 
for the latter is the phenolic acid homogentisic acid, which is markedly elevated in blood and 
urine specifically in alkaptonuria (AKU, OMIM 203500), a disorder of phenylalanine and 
tyrosine degradation 2,3. Importantly, this metabolite is not only found elevated but also 
considered central for the many complications of AKU, which mainly occur not before 
adulthood. Unfortunately, once developed, these complications, of which damage to ochronotic 
tissue resulting in premature spondyloarthritis, tendon ruptures, cardiac valve disease, and 
nephropathy are the most prominent, are irreversible.  
Given the fact that complications in AKU occur only after many years of exposure to 
homogentisic acid but are then irreversible, clinical endpoints in testing efficacy of 
homogentisic acid-lowering therapies are prone to fail. Rather, based on the well-known natural 
course of the disease 2,3 and on knowledge from mouse models 4,5, homogentisic acid with its 
superior impact on the pathogenesis in this condition should not only be seen as marker for the 
disease but also as a suitable endpoint of clinical trials. This was done by Lakshminarayan 
Ranganath and colleagues from multiple European sites in a study that was long waited for in 
the metabolic community 6. Since a blinded control study for AKU is not feasible as urinary 
changes with homogentisic acid-lowering therapy will unveil any blind design (urine color 
turning from dark/black in untreated disease condition to normal color under treatment), 
performing a convincing study is all the more challenging and an innovative study design is 
mandatory 7. The current authors now were able to show a decrease in homogentisic acid 
excretion in AKU patients under nitisinone, and they additionally demonstrated statistically 
significant effects on some clinical outcomes 6.  
The paper is important for the management of AKU. So far, treatment was symptomatic and 
this meant the handling of inevitable ochronotic complications. Here, for a first time, not only 
biochemical “cure” but also clinical impact was demonstrated in a large cohort. This gives hope 
that the course of disease in AKU can be fundamentally changed in the future.  
Nevertheless, open questions remain: 
• When do we have to start treatment? After what age become the ochronotic changes 
irreversible and clinically relevant? For this, additional studies are needed to determine 
the ochronotic process during presymptomatic years and defining the optimal time point 
for start of treatment. 
• What is the optimal dose of nitisinone? One consequence of treatment with nitisinone 
will be an increase of tyrosine in blood that may cause keratopathy. Patients on 
treatment will therefore require a phenylalanine and tyrosine reduced diet, which 
impacts on their quality of life. For (not only) this reason, the minimum effective dose 
of nitisinone should be used and this needs to be determined in future trials.  
• Will all patients need to be treated? If in a patient homogentisic acid is only increased 
moderately, is there likewise a benefit through homogentisic acid-lowering treatment?  
In summary, the present study is remarkable in more than one aspect. First, AKU is an ultra-
rare condition affecting only 1 in 250.00 to 1.000.000 people. To recruit 138 patients under 
these circumstances is simply extraordinary. Then, the study was designed as a combination of 
a very meaningful biochemical parameter together with clinical outcomes, and this combination 
of endpoints, while being unconventional, seems ideal for this very slowly progressing disease. 
Finally, this study gives hope that the treatment of AKU will change from a purely symptomatic 
therapy to prevention of complications and therefore a much improved outcome of affected 
patients. It is remarkable that this study is finally accomplished almost 22 years after the first 
suggestion of “multisystemic salutary effects” of nitisinone as an option to cure alkaptonuria 8. 
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